A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Tasisulam (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 07 Nov 2008 Added actual patient number and end date, based on information from ClinicalTrials.gov.
- 06 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 07 Jun 2007 Status changed from suspended to recruiting.